499 related articles for article (PubMed ID: 22344941)
1. Mammalian target of rapamycin: a valid therapeutic target through the autophagy pathway for Alzheimer's disease?
Cai Z; Zhao B; Li K; Zhang L; Li C; Quazi SH; Tan Y
J Neurosci Res; 2012 Jun; 90(6):1105-18. PubMed ID: 22344941
[TBL] [Abstract][Full Text] [Related]
2. Alteration of the Wnt/GSK3β/β‑catenin signalling pathway by rapamycin ameliorates pathology in an Alzheimer's disease model.
Chen J; Long Z; Li Y; Luo M; Luo S; He G
Int J Mol Med; 2019 Jul; 44(1):313-323. PubMed ID: 31115485
[TBL] [Abstract][Full Text] [Related]
3. mTOR/p70S6k signalling alteration by Abeta exposure as well as in APP-PS1 transgenic models and in patients with Alzheimer's disease.
Lafay-Chebassier C; Paccalin M; Page G; Barc-Pain S; Perault-Pochat MC; Gil R; Pradier L; Hugon J
J Neurochem; 2005 Jul; 94(1):215-25. PubMed ID: 15953364
[TBL] [Abstract][Full Text] [Related]
4. [Involvement of beta-amyloid in the etiology of Alzheimer's disease].
Tomiyama T
Brain Nerve; 2010 Jul; 62(7):691-9. PubMed ID: 20675873
[TBL] [Abstract][Full Text] [Related]
5. Amyloid precursor protein cytoplasmic domain with phospho-Thr668 accumulates in Alzheimer's disease and its transgenic models: a role to mediate interaction of Abeta and tau.
Shin RW; Ogino K; Shimabuku A; Taki T; Nakashima H; Ishihara T; Kitamoto T
Acta Neuropathol; 2007 Jun; 113(6):627-36. PubMed ID: 17431643
[TBL] [Abstract][Full Text] [Related]
6. Alteration of mTOR signaling occurs early in the progression of Alzheimer disease (AD): analysis of brain from subjects with pre-clinical AD, amnestic mild cognitive impairment and late-stage AD.
Tramutola A; Triplett JC; Di Domenico F; Niedowicz DM; Murphy MP; Coccia R; Perluigi M; Butterfield DA
J Neurochem; 2015 Jun; 133(5):739-49. PubMed ID: 25645581
[TBL] [Abstract][Full Text] [Related]
7. [Therapy of Alzheimer disease].
Kovács T
Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
[TBL] [Abstract][Full Text] [Related]
8. Selenomethionine Attenuates the Amyloid-β Level by Both Inhibiting Amyloid-β Production and Modulating Autophagy in Neuron-2a/AβPPswe Cells.
Zhang ZH; Wu QY; Chen C; Zheng R; Chen Y; Liu Q; Ni JZ; Song GL
J Alzheimers Dis; 2017; 59(2):591-602. PubMed ID: 28671121
[TBL] [Abstract][Full Text] [Related]
9. Inducing autophagy by rapamycin before, but not after, the formation of plaques and tangles ameliorates cognitive deficits.
Majumder S; Richardson A; Strong R; Oddo S
PLoS One; 2011; 6(9):e25416. PubMed ID: 21980451
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease.
Spilman P; Podlutskaya N; Hart MJ; Debnath J; Gorostiza O; Bredesen D; Richardson A; Strong R; Galvan V
PLoS One; 2010 Apr; 5(4):e9979. PubMed ID: 20376313
[TBL] [Abstract][Full Text] [Related]
11. Protopanaxadiol derivative DDPU improves behavior and cognitive deficit in AD mice involving regulation of both ER stress and autophagy.
Guo X; Lv J; Lu J; Fan L; Huang X; Hu L; Wang J; Shen X
Neuropharmacology; 2018 Mar; 130():77-91. PubMed ID: 29197516
[TBL] [Abstract][Full Text] [Related]
12. Autophagic dysfunction in Alzheimer's disease: Cellular and molecular mechanistic approaches to halt Alzheimer's pathogenesis.
Uddin MS; Mamun AA; Labu ZK; Hidalgo-Lanussa O; Barreto GE; Ashraf GM
J Cell Physiol; 2019 Jun; 234(6):8094-8112. PubMed ID: 30362531
[TBL] [Abstract][Full Text] [Related]
13. Wogonin increases β-amyloid clearance and inhibits tau phosphorylation via inhibition of mammalian target of rapamycin: potential drug to treat Alzheimer's disease.
Zhu Y; Wang J
Neurol Sci; 2015 Jul; 36(7):1181-8. PubMed ID: 25596147
[TBL] [Abstract][Full Text] [Related]
14. Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments.
Caccamo A; Majumder S; Richardson A; Strong R; Oddo S
J Biol Chem; 2010 Apr; 285(17):13107-20. PubMed ID: 20178983
[TBL] [Abstract][Full Text] [Related]
15. Genetic reduction of mammalian target of rapamycin ameliorates Alzheimer's disease-like cognitive and pathological deficits by restoring hippocampal gene expression signature.
Caccamo A; De Pinto V; Messina A; Branca C; Oddo S
J Neurosci; 2014 Jun; 34(23):7988-98. PubMed ID: 24899720
[TBL] [Abstract][Full Text] [Related]
16. Autophagy dysfunction in Alzheimer's disease.
Li L; Zhang X; Le W
Neurodegener Dis; 2010; 7(4):265-71. PubMed ID: 20551691
[TBL] [Abstract][Full Text] [Related]
17. The immunosuppressant rapamycin exacerbates neurotoxicity of Abeta peptide.
Lafay-Chebassier C; Pérault-Pochat MC; Page G; Rioux Bilan A; Damjanac M; Pain S; Houeto JL; Gil R; Hugon J
J Neurosci Res; 2006 Nov; 84(6):1323-34. PubMed ID: 16955484
[TBL] [Abstract][Full Text] [Related]
18. Anti-autophagic and anti-apoptotic effects of memantine in a SH-SY5Y cell model of Alzheimer's disease via mammalian target of rapamycin-dependent and -independent pathways.
Song G; Li Y; Lin L; Cao Y
Mol Med Rep; 2015 Nov; 12(5):7615-22. PubMed ID: 26459718
[TBL] [Abstract][Full Text] [Related]
19. Metformin Facilitates Amyloid-β Generation by β- and γ-Secretases via Autophagy Activation.
Son SM; Shin HJ; Byun J; Kook SY; Moon M; Chang YJ; Mook-Jung I
J Alzheimers Dis; 2016; 51(4):1197-208. PubMed ID: 26967226
[TBL] [Abstract][Full Text] [Related]
20. mTOR regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies.
Caccamo A; Magrì A; Medina DX; Wisely EV; López-Aranda MF; Silva AJ; Oddo S
Aging Cell; 2013 Jun; 12(3):370-80. PubMed ID: 23425014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
